Inventory

3 Months Ended

Mar. 31, 2022

Inventory Disclosure [Abstract]

Inventory

(4) Inventory

The Company capitalizes its purchases of saleable inventory of VASCEPA from suppliers that have been qualified by the U.S. FDA. Inventories as of March 31, 2022 and December 31, 2021 consist of the following:

In thousands	March 31, 2022		December 31, 2021
Raw materials	$	123,318	$	107,695
Work in process		56,217		41,965
Finished goods		229,335		206,270
Total inventory	$	408,870	$	355,930

As of March 31, 2022 and December 31, 2021, the Company had $141.1 million and $121.3 million of Long-term inventory, respectively, as consumption is expected beyond the Company's normal operating cycle.